2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2015 Featured Talks » Preclinical and Clinical Cancer Stem Cell Detection and Elimination



Catriona Jamieson, part 1 from MCC Industry Relations on Vimeo.



Catriona Jamieson, part 2 from MCC Industry Relations on Vimeo.






Catriona Jamieson, MD, PhD
Associate Professor, Division of Hematology-Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Chief, Division of Regenerative Medicine, UC San Diego
Director, Stem Cell Research at UC San Diego Moores Cancer Center
Co-Director of the UC San Diego Stem Cell Training Program


Catriona Jamieson, MD, PhD is the inaugural chief of the new Division of Regenerative Medicine, in the Department of Medicine at UC San Diego. Dr. Jamieson joined the UC San Diego faculty in 2005 and is an associate professor of Medicine in the Division of Hematology-Oncology. She has proven her leadership skills, expertise and effectiveness in her current positions as director of the Stem Cell Research Program at Moores Cancer Center, co-leader of the Hematologic Malignancies Program, hematology team leader, co-director of the UC San Diego Stem Cell Training Grant, coordinating course director of the Interdisciplinary Stem Cell course, and a co-director of the new Sanford Stem Cell Clinical Center.

Dr. Jamieson specializes in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies.